MyChesCo on MSN2d
Navrogen Advances Antibody Technology to Combat Cancer with New Findings
Navrogen, Inc. has announced groundbreaking advancements in monoclonal antibody (mAb) and antibody-drug conjugate (ADC) ...
MedPage Today on MSN17d
Myasthenia Gravis Antibody Types
Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR antibodies), ...
Medical Dialogues12d
FDA Approves First oral Treatment for rare Glomerulopathy
The US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in ...
pharmaphorum13d
Fabhalta is first FDA-approved therapy for rare disease C3G
Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting ...
Nature3mon
New approaches for managing antiphospholipid syndrome
Patients with catastrophic APS usually receive a combination of anticoagulants, corticosteroids, intravenous immunoglobulin ... rituximab, complement inhibition, and other targeted therapies ...
Healthline8d
Intravenous Immunoglobulin (IVIG) for the Treatment of Crohn’s Disease
Intravenous immunoglobulin (IVIG) is one treatment option. Crohn’s disease is a type of inflammatory bowel disease (IBD) that affects an estimated a million people in the United States.